You are here

Article Text

Article menu
Download PDFPDF
Case report
Acute icteric hepatitis as the first isolated symptom of COVID-19
  1. Pierre-Clément Thiebaud,
  2. Christelle Hermand,
  3. Jennifer Sobotka and
  4. Pierre-Alexis Raynal
  1. Emergency Department, Hôpital Saint-Antoine, Assistance Publique - Hôpitaux de Paris, Sorbonne Université, Paris, France
  1. Correspondence to Dr Pierre-Clément Thiebaud; pierre-clement.thiebaud{at}aphp.fr

Abstract

Patients with COVID-19 may be asymptomatic or present with extrarespiratory symptoms, such as liver injury. It has been reported that 22.5%–46.2% of patients have moderate elevation of liver enzymes. To our knowledge, acute hepatitis has never been described as an isolated symptom of COVID-19 in a previously healthy patient. We report the case of a 53-year-old patient with COVID-19 whose first clinical presentation was acute icteric hepatitis, several days before the development of others symptoms. During the pandemic, we suggest that patients with acute hepatitis be considered as COVID-19 suspects, tested and isolated.

  • COVID-19
  • hepatitis and other GI infections
  • hepatitis other

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

https://doi.org/10.1136/bcr-2021-242853

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors P-CT: involved in patient management, literature search and initial drafting of the manuscript; CH: involved in patient management and final drafting of the manuscript; JS: involved in patient management and final drafting of the manuscript; P-AR: involved in final drafting of the manuscript. All authors read and approved the final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.